Clinical Trial Update: Short-term Effects of Dapagliflozin on Peak VO2 in HFrEF [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the short-term effects of dapagliflozin on peak VO2 in patients with heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 4 | Status: COMPLETED